

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on May 15, 2006

PATENT  
Attorney Docket No.: 082368-001100US  
Client Reference No.: M3-A0201P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Aaron Hokamura/  
Aaron Hokamura

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

**MASAI and TAMAI**

Application No.: 10/507,275

371(c) Date: June 8, 2005

Int'l Application No.: PCT/JP03/02918

Int'l Filing Date: March 12, 2003

For: CDC7-ASK KINASE COMPLEX,  
SUBSTRATES OF THE KINASE  
COMPLEX, SPECIFIC ANTIBODIES  
TO THE SUBSTRATES, AND  
SCREENING METHODS USING THE  
SAME TO SCREEN FOR COMPOUNDS  
COMPRISING CDC7-ASK KINASE  
INHIBITORY ABILITY

Confirmation No.:

Examiner:

Art Unit:

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
80774121 v1

Substitute for form 1449A&B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/507,275
				Filing Date	March 12, 2003
				First Named Inventor	Masai, Hisao
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	082368-001100US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup>				
	AF	WO	01/96557	A2/A3	12-20-2001	Pharmacia & Upjohn SPA	<input type="checkbox"/>
	AG	EP	1 125 947	A1	08-22-2001	Japan Science and Technology Corporation; Kenichi Arai, and Hisao Masai	<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AH	OGINO, Keiko et al.; "Bipartite binding of a kinase activator activates Cdc7-related kinase essential for S phase"; <u>The Journal of Biological Chemistry</u> ; August 17, 2001; pp. 31376-31387; Vol. 276, No. 33	<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

\* EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.